Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Xience V More Significantly Reduces MACE than Taxus: Abbott
April 25, 2011
- Novartis Discontinues PIII Study of Tasigna in GIST
April 25, 2011
- Wholesalers Less Pessimistic than Manufacturers about Quake's Effects on Demand
April 25, 2011
- Korosho Wants Industry “As a Whole”to Meet Power Cut Targets
April 25, 2011
- 4 Unapproved Indications Considered to Have Unmet Medical Needs: Council
April 25, 2011
- The Great East Japan Earthquake: MRs in the Disaster Zone
April 25, 2011
- No Company Subject to Penalty due to Failure to Develop Designated Unapproved Drugs/Indications
April 25, 2011
- Lantus Obtains 60% Market Share: sanofi-aventis
April 25, 2011
- PAFSC 1st Committee to Review Liovel, Nexium
April 25, 2011
- FJPWA May Have to Consider Rotational Operations: FJPWA President Bessho
April 25, 2011
- Korosho Draws up GL for R&D Use of Donated Blood
April 25, 2011
- Takeda Accelerating Tie-ups in CNS Field
April 18, 2011
- Pharmacists to Participate in Dispensing Bill Review Starting in June
April 18, 2011
- Domestic Generics-only Makers to Maintain Lead in GE Drug Market: Report
April 18, 2011
- DSP, BBI Enter Strategic Partnership on Anticancer Drugs
April 18, 2011
- Regulatory Reform Shelves Online Sale of OTC Drugs, Unification of Basic Dispensing Fees
April 18, 2011
- Nippon Chemiphar Introduces MR Team System on a Full Scale
April 18, 2011
- Eisai Reorganizes Its Businesses in East Asia
April 18, 2011
- Korosho Draws Up New GL for Clinical Evaluation of Drugs for Heart Failure
April 18, 2011
- Sawai's Cetirizine OD Tab Receives Generic Drug of Year Award
April 18, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…